Leiden, July 2025 – Genlumina has received a grant from the Province of South Holland under the MIT (SME Innovation Stimulation) program to support a feasibility study for its innovative cancer therapy, Silver Bullet.

The study explores a light-activated therapeutic that selectively targets tumor cell nuclei, leaving healthy cells unharmed. This approach combines nanotechnology with advanced light delivery techniques and aims to revolutionize precision oncology.

The project aligns with the province’s ambition to foster a sustainable and innovative economy. The grant supports Genlumina’s efforts to validate the scientific and technical viability of its therapy and prepare for future clinical development.

“We are grateful for this support, which strengthens our mission to develop safer and more effective cancer treatments,”, said CEO Gerco Kanbier.

For more information or collaboration opportunities, please contact us